BrinDx aims to revolutionize the diagnosis and monitoring of neurodegenerative diseases for patients, physicians, and clinical research organizations globally. Our diagnostic platform is designed to target the main biomarkers of these diseases, which begin to accumulate in the brain at the initial stages, therefore, allowing for early detection and intervention.

We are currently developing a pipeline for the discovery of a novel class of radiotracers for neurodegenerative diseases. This platform is based on the knowledge obtained as a result of more than 20 years of experience of our team of scientists, coupled with the latest cutting-edge technology in the field of neurodiagnostics.

We are developing a pioneering diagnostic technology equipped with a capture molecule rigorously engineered to selectively target toxic biomarkers associated with neurodegenerative disorders. This innovative method enables precise quantification of aggregated protein species in bodily fluids, unlocking vast potential for early disease detection. We're redefining the landscape of neurodegenerative care, offering early detection as the cornerstone of effective intervention and improved patient outcomes.